journal
MENU ▼
Read by QxMD icon Read
search

Expert Opinion on Pharmacotherapy

journal
https://www.readbyqxmd.com/read/28820270/second-line-treatment-options-for-pancreatic-cancer
#1
Frank C Passero, Muhammad Wasif Saif
ABTRACT Introduction: Patients with advanced pancreatic cancer (APC) refractory to first-line therapy have a dismal prognosis and limited therapeutic options, with only one option consisting of nanoliposomal irinotecan in combination with fluorouracil and folinic acid which was approved by FDA based upon results of the phase III NAPOLI-1 study. Areas covered: We performed a literature search for relevant published clinical trials, abstracts of trials in progress and ongoing or planned trials for the second line treatment of APC using Pubmed...
August 18, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28820000/novel-combination-strategies-for-enhancing-efficacy-of-immune-checkpoint-inhibitors-in-the-treatment-of-metastatic-solid-malignancies
#2
Michael J Flynn, James M G Larkin
Immune-checkpoint inhibitor (ICPI) drugs, which include antibodies against CTLA-4, PD-1 and PD-L1, have been shown to induce durable complete responses in a proportion of patients with particular efficacy demonstrated in both the first line and refractory setting in advanced NSCLC and melanoma. However, these drugs remain effective only in a minority of unselected patients. Areas covered: This review will focus on mechanisms of resistance to ICPI and underline the importance of identification of novel predictive markers of responsiveness...
August 18, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28812387/reply-to-recent-advances-in-systemic-targeted-therapy-for-cutaneous-t-cell-lymphoma
#3
Teresa Amaral, Claus Garbe
No abstract text is available yet for this article.
August 16, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28803489/recent-advances-in-systemic-targeted-therapy-for-cutaneous-t-cell-lymphoma
#4
Daniel J Lewis, Ellen J Kim, Madeleine Duvic
No abstract text is available yet for this article.
August 14, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28799819/no-cardiovascular-benefit-with-evacetrapib-is-this-the-end-of-the-road-for-the-cetrapibs
#5
Sheila A Doggrell
Introduction Increasing high-density lipoprotein(HDL) cholesterol levels predict improved cardiovascular outcomes. However, inhibiting cholesteryl ester transfer protein (CETP) to increase HDL cholesterol, with the 'cetrapibs' (torcetrapib and dalcetrapib), did not improve cardiovascular clinical outcomes. Despite these findings, the clinical outcomes trial with evacetrapib continued. Areas covered Treatment with evacetrapib increased the levels of HDL by ~130%, and decreased low-density lipoprotein (LDL) cholesterol by ~37%...
August 11, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28786696/once-versus-twice-daily-direct-oral-anticoagulants-in-non-valvular-atrial-fibrillation
#6
Walter Ageno, Jan Beyer-Westendorf, Andrea Rubboli
Direct oral anticoagulants (DOACs) have emerged as alternatives to vitamin K antagonists for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). Four DOACs: dabigatran, rivaroxaban, apixaban and edoxaban, are currently available. In the absence of head-to-head clinical comparisons of DOACs, dosing regimen may influence drug choice. Areas covered: Edoxaban and rivaroxaban are administered once daily, dabigatran and apixaban twice daily. The selection of these dosage regimens is largely based on studies for the prevention or treatment of venous thromboembolism or acute coronary syndrome...
August 11, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28764603/luteininzing-hormone-releasing-hormones-analogs-in-combination-with-tamoxifen-for-the-adjuvant-treatment-of-premenopausal-women-with-hormone-receptor-positive-breast-cancer
#7
Benedetta Conte, Francesca Poggio, Lucia Del Mastro
The role of ovarian function suppression (OFS) through luteinizing hormone-releasing hormone agonists (LHRHa) in addition to tamoxifen has been questioned until recently. In 2015, two large clinical trials led to a paradigm shift in the adjuvant endocrine treatment of premenopausal women, introducing the use of LHRHa plus tamoxifen (or aromatase inhibitor, AI) into current clinical practice. Areas covered: The present review aims to provide an in-depth overview of the role of LHRHa+tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer (HR+BC)...
August 10, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28741385/efficacy-and-safety-of-teneligliptin-add-on-to-insulin-monotherapy-in-japanese-patients-with-type-2-diabetes-mellitus-a-16-week-randomized-double-blind-placebo-controlled-trial-with-an-open-label-period
#8
Takashi Kadowaki, Kazuoki Kondo, Noriyuki Sasaki, Kyoko Miyayama, Shoko Yokota, Ryuji Terata, Maki Gouda
OBJECTIVE: To assess the efficacy and safety of teneligliptin as add-on to insulin monotherapy in patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: In a 16-week, double-blind period, 148 Japanese T2DM patients with inadequate glycemic control with insulin and diet/exercise therapies were randomized to placebo or teneligliptin 20 mg. In a subsequent 36-week, open-label period, all patients received teneligliptin once daily. The primary outcome measure was change in HbA1c at the end of the double-blind period...
August 10, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28764565/fluocinolone-acetonide-for-the-treatment-of-diabetic-macular-edema
#9
Daniele Veritti, Valentina Sarao, Laura Diplotti, Francesco Samassa, Paolo Lanzetta
Fluocinolone acetonide intravitreal implant is a non-erodible implant approved for the treatment of diabetic macular edema (DME) insufficiently responsive to available therapies. Areas covered: The injectable intravitreal implant releases fluocinolone acetonide at an average rate of 0.2 µg/day for at least 36 months. The two pooled pivotal FAME trials showed that, in patients with DME previously treated with laser photocoagulation, fluocinolone acetonide intravitreal implant was more beneficial than sham injection when looking at the proportion of patients with an improvement from baseline in visual acuity of more than 15 letters at 24 months and at 36 months...
August 9, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28786691/current-and-developing-therapies-for-the-treatment-of-multi-drug-resistant-tuberculosis-mdr-tb-in-india
#10
M Muniyandi, Rajeswari Ramachandran
India accounts for 25% of the global burden of MDR-TB. In 2016, the India's Revised National TB Control Programme reported a success rate of 46% among 19298 MDR-TB patients treated under the programme. This suboptimal treatment outcome warrants an urgent need for newer drugs and newer regimens in the treatment of MDR-TB. India requires new shorter, cheap, safe and effective anti-TB regimen to treat MDR-TB. Areas covered: We used different search strategies to obtain relevant literature from PubMed, on Indian experiences of developing therapies for the treatment of MDR-TB...
August 8, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28780896/addressing-the-unmet-needs-of-current-antidepressants-does-neuroscience-help-or-hinder-clinical-psychopharmacology-research
#11
Joseph F Goldberg, A John Rush
No abstract text is available yet for this article.
August 7, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28756718/pharmacotherapy-of-glaucoma-new-opportunities-old-challenges
#12
Andreas Katsanos, Anna I Dastiridou
No abstract text is available yet for this article.
August 7, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28754071/a-review-of-pharmacotherapy-for-treating-gastroesophageal-reflux-disease-gerd
#13
Edoardo Savarino, Patrizia Zentilin, Elisa Marabotto, Giorgia Bodini, Marco Della Coletta, Marzio Frazzoni, Nicola de Bortoli, Irene Martinucci, Salvatore Tolone, Gaia Pellegatta, Vincenzo Savarino
Medical therapy of gastroesophageal reflux disease (GERD) is based on the use of proton pump inhibitors (PPIs) as first choice treatment. Despite their effectiveness, about 20-30% of patients report an inadequate response and alternative drugs are required. Areas covered: This review provides an overview of current pharmacotherapy for treating GERD by showing the results of PPIs, reflux inhibitors, antidepressants and mucosa protective medications. Expert opinion: Medical therapy of GERD does not definitely cure the disease, because even PPIs are not able to change the key factors responsible for it...
August 7, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28750572/small-molecules-as-therapy-for-uveitis-a-selected-perspective-of-new-and-developing-agents
#14
Uwe Pleyer, Engi Abdel-Hady Algharably, Eugen Feist, Reinhold Kreutz
Intraocular inflammation (uveitis) remains a significant burden of legal blindness. Because of its immune mediated and chronic recurrent nature, common therapy includes corticosteroids, disease-modifying anti-rheumatic drugs and more recently biologics as immune modulatory agents. The purpose of this article is to identify the role of new treatment approaches focusing on small molecules as therapeutic option in uveitis. Areas covered: A MEDLINE database search was conducted through February 2017 using the terms 'uveitis' and 'small molecule'...
August 7, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28756724/medical-expulsive-therapy-in-urolithiasis-a-mixed-treatment-comparison-network-meta-analysis-of-randomized-controlled-clinical-trials
#15
Kannan Sridharan, Gowri Sivaramakrishnan
BACKGROUND: Medical expulsive therapy (MET) using alpha blockers, calcium channel blockers (CCB), phosphodiesterase inhibitors (PDEI) and spasmolytics have been shown to be effective in clinical trials on urolithiasis. The present study is a network meta-analysis comparing the above mentioned drug classes. RESEARCH DESIGN AND METHODS: Electronic databases were searched for randomized controlled trials comparing the above mentioned drug classes in patients with urolithiasis using appropriate search strategy...
August 4, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28770629/ipragliflozin-a-sodium-glucose-co-transporter-2-inhibitor-reduces-intrahepatic-lipid-content-and-abdominal-visceral-fat-volume-in-patients-with-type-2-diabetes
#16
Akio Ohta, Hiroyuki Kato, Satoshi Ishii, Yosuke Sasaki, Yuta Nakamura, Tomoko Nakagawa, Yoshio Nagai, Yasushi Tanaka
OBJECTIVE: We recently investigated the effect of ipragliflozin, a sodium glucose co-transporter-2 inhibitor (SGLT-2I), in Japanese patients with type 2 diabetes by a 24-week. SGLT-2Is also have an anti-obesity effect, and reduction of body fat has been demonstrated by indirect methods. However, evaluation of the effect on the total visceral fat volume and intrahepatic lipid content has not been performed. RESEARCH DESIGN AND METHODS: We measured the abdominal subcutaneous fat volume (SFV) and visceral fat volume (VFV) by whole abdominal CT scanning, the intrahepatic lipid (IHL) content by proton magnetic resonance spectroscopy (1H-MRS), and the fat mass index (FI) and appendicular skeletal mass index (ASMI) by dual X-ray absorptiometry (DXA) in 20 patients from our previous study...
August 3, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28764578/developments-in-early-diagnosis-and-therapy-of-hiv-infection-in-newborns
#17
Francisco Canals, Mar Masiá, Félix Gutiérrez
Infants who acquire HIV have an exceptionally high risk of morbidity and mortality if they do not receive antiretroviral therapy (ART). Areas covered: This review aims to summarize the currently available evidence on ART in HIV-infected neonates. Data were obtained from literature searches from PubMed, abstracts from International Conferences (2000-2017), and authors' files. Expert opinion: Current evidence favors early diagnosis and prompt ART of HIV infection in newborns. The precise timing of initiation of ART remains undetermined...
August 2, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28730885/ataluren-in-cystic-fibrosis-development-clinical-studies-and-where-are-we-now
#18
Noreen Zainal Abidin, Iram J Haq, Aaron I Gardner, Malcolm Brodlie
Cystic fibrosis (CF) is one of the most common genetically-acquired life-limiting conditions worldwide. The underlying defect is dysfunction of the cystic fibrosis transmembrane-conductance regulator (CFTR) which leads to progressive lung disease and other multi-system effects. Around 10% of people with CF have a class I nonsense mutation that leads to production of shortened CFTR due to a premature termination codon (PTC). Areas covered: We discuss the discovery of the small-molecule drug ataluren, which in vitro has been shown to allow read-through of PTCs and facilitate synthesis of full-length protein...
August 1, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28675065/hypomethylating-agents-hma-treatment-for-myelodysplastic-syndromes-alternatives-in-the-frontline-and-relapse-settings
#19
Natalie Uy, Abhay Singh, Steven D Gore, Thomas Prebet
Hypomethylating agents (HMA) have played a pivotal role for treating myelodysplastic syndromes (MDS) over the past decade, inducing sustained hematological responses and delaying progression to leukemia. However, a vast majority of patients will experience treatment failure within 2 years, with poor prognoses and limited options, and management of this growing patient population remains unclear. Areas covered: With the introduction of new agents in the MDS field, a better understanding of the biology of MDS, and updated information on standard of care options (including allogeneic transplantation), we re-evaluate the global treatment strategy in MDS via novel agents, focusing in particular on investigational approaches for patients who fail to respond to HMA when applicable...
August 1, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28644739/treatment-of-hepatitis-c-with-new-fixed-dose-combinations
#20
Vincent Soriano, José V Fernandez-Montero, Carmen de Mendoza, Laura Benitez-Gutierrez, José M Peña, Ana Arias, Pablo Barreiro
The advent of oral direct-acting antivirals (DAA) has revolutionized the hepatitis C virus (HCV) therapeutic landscape providing cure rates over 90%. However, a subset of patients remains at higher risk for treatment failure, including those infected with: i) genotype 3 and cirrhosis; ii) resistance-associated substitutions (RAS) occurring either as natural polymorphisms or selected after prior DAA failure; and iii) poor drug adherence associated with social disabilities (homeless, psychiatric illnesses, injection drug use, alcoholism, etc...
July 30, 2017: Expert Opinion on Pharmacotherapy
journal
journal
34813
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"